Atypical phosphatase DUSP11 inhibition promotes nc886 expression and potentiates gemcitabine-mediated cell death...

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal cancer with limited treatment options.
• Gemcitabine (Gem) is a first-line treatment, but drug resistance remains a significant challenge.
• Understanding signaling feedback loops, particularly phosphatases, is crucial for overcoming resistance.

Purpose of the Study:

• To identify dual-specificity phosphatases (DUSP) involved in gemcitabine response in PDAC.
• To investigate the role of DUSP11 in mediating resistance to gemcitabine in PDAC cells.
• To elucidate the molecular mechanisms by which DUSP11 affects gemcitabine sensitivity.

Main Methods:

• CRISPR/Cas9-based phenotypic screening to identify relevant DUSP family members.
• In vitro experiments assessing cell survival, apoptosis, and cytotoxicity upon DUSP11 inhibition and gemcitabine treatment.
• In silico transcriptome analysis (RNA-seq) of PDAC patient samples.
• Western blot analysis to assess protein phosphorylation and signaling pathway activation.

Main Results:

• A CRISPR screen identified DUSP11 as a key regulator of gemcitabine response in PDAC.
• Genetic inhibition of DUSP11 sensitized PDAC cells to gemcitabine, enhancing cytotoxicity and apoptosis.
• DUSP11 upregulation correlated with NF-κB signaling pathway activation in PDAC patient data.
• DUSP11 inhibition blocked gemcitabine-induced NF-κB phosphorylation and modulated the PKR-NF-κB cascade via nc886.

Conclusions:

• DUSP11 is a critical RNA phosphatase that confers resistance to gemcitabine in pancreatic cancer.
• Inhibiting DUSP11 represents a potential therapeutic strategy to improve gemcitabine efficacy in PDAC.
• This study reveals novel insights into DUSP11's role in RNA biology and cancer drug resistance.